ライブ
FierceBiotechEthyreal Bio manifests with $101M in pack of biotechs gunning for Amgen’s TepezzaEndpoints NewsShattuck raises $75M; Servier inks neuro ASO pact with n-Lorem FoundationEndpoints NewsBiotech pay analysis: 12 execs with $35M+ M&A golden parachutesBioPharma DiveAstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicineFierceBiotechNovartis sticks 2nd deal with molecular glue biotech Orionis, this one worth up to $1.4BBioWorldShenzhen Chipscreen Biosciences synthesizes new HDAC inhibitorsBioWorldKunming Taita Biotech discovers new angiogenesis inhibitorsBioWorldJiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonistsBioWorldColumbia researchers use base editing to modify human embryo genomeLabiotechHow Daiichi Sankyo aims to become a top five oncology player by 2035PharmaVoiceAmid a flurry of biotech deals, China looks to keep innovation at homeCellPrion-based protein self-assembly tunes mutagenesis to enable rapid adaptation
Endpoints News 2026年1月7日

Poplar Therapeutics gets $50M Series A for immunology ambitions

Poplar Therapeutics gets $50M Series A for immunology ambitions

原文
本文は利用できません。元の情報源をご確認ください。